Health care spending in the U.S. is expected to double by 2016 to $4.1 trillion!!
CAEH could become a big player in a market this large!
It's been said that the biopharmaceutical industry spends $21 billion annually on research.
So many bio-pharma companies are in the lab focused on vaccines for swine flu.
What about age-old problems such as hypertension and diabetes that are spreading fast around the world?
It is estimated that over 200 million people in North and South America suffer from established cardiovascular conditions as well as dysmetabolic syndromes such as pre-diabetes, pre-hypertension and metabolic syndrome.
According to a report by the Institute of Medicine, some 2.7 million to 3.9 million Americans are estimated to have hepatitis C, and 12,000 die from it each year!
CAEH is dedicated to meeting these challenges!
CAEH's pipeline is composed of over-the-counter and prescription medications including its proprietary antiviral and "Liver Health" OTC formulations.
Caleco is also developing over-the-counter food supplements and dermatological products based on the active ingredients found in its proprietary formulation.
To date, CAEH's intellectual property covering the Liver Health formulations and derivatives consists of patent applications in the United States, Europe and Canada and four European Drug Master File applications!
The CAEH pipeline includes CPC.12115HP201 and CPC.12115HP202. Both products are derivatives of the Corporations “Liver Health” formulations.
CAEH's patent protected product line targets a segment of the market that includes millions of people suffering from various liver maladies, especially the Hepatitis C Virus (HCV).
Lamiridosin is an oral supplement derived from the Corporation’s “Liver Health” formulation and is being prepared for worldwide market launches in late 2010 and early 2011!
CAEH has a strategic alliance with NATAC Biotech, S.L. (a Spanish biotechnology corporation engaged in the research and development of health related products) that provides first look access to compounds from one of the world's leading pharmacognosy research centers!
In February CAEH signed a Laboratory Facilities and Service Agreement with Natac Biotech S.L. ("Natac").
Under the terms of the Lab Facilities and Services Agreement, Natac, through its subsidiary Natac Research, has agreed to provide CAEH with the services of senior research scientists and the associated laboratory facilities, which are located at the Universidad Autonoma de Madrid.
Based in Madrid, Spain, Natac Biotech S.L., specializes in deriving functional foods and active ingredients from natural substances.
NATAC has an alliance with the Universidad Autónoma de Madrid, one of continental Europe's premier biotech research facilities, which provides CAEH with access to more than 1,200 square meters of laboratory facilities!
By tapping the results of an elite group of researchers and scientists at the university, CAEH and Natac are well positioned to make significant advances in the development of their co-license product pipeline.
The CAEH pipeline targets large health care market segments in North America, South America and Europe with over 200MM potential customers!
The CAEH product pipeline now includes compounds with anti-inflammatory and metabolic effects that may prove beneficial in promoting cardiovascular and metabolic health.
Over 100 million people worldwide are believed to have chronic metabolic dysfunction status whom may potentially benefit from these types of supplements!
This past March CAEH entered into an exclusive license agreement with Natac whereby Natac granted CAEH the exclusive right to develop, commercialize, market and distribute five compounds derived from plant extracts throughout North and South America.
The License Agreement also provides that CAEH will have the right to sub-license the five compounds in North and South America.
The natural biopharma sector has been rapidly growing and CAEH is bridging the pharmaceutical world with the newly evolving nutraceutical and cosmeceutical worlds.
Cosmetic Project Management, a Spanish corporation that provides product and market development support to cosmetic product manufacturers, has delivered to CAEH the commercial formulations of its Natural Hair Care Products (LamiriShampoo, LamiriHair Conditioner, LamiriHair Tonic) and Natural Skin Care Products (LamiriGel and LamiriCreme).
CAEH's dermatologic products are of particular interest due to their "natural" sourcing and potential for efficacy.
The Global nutraceuticals marketplace is estimated to reach approximately $200 billion dollars in 2010-2011!
The nutraceutical marketplace is growing worldwide for several reasons including:
(1) A growing middle class with greater emphasis on specialty nutrition, preventive medicine and self-care.
(2) A population increasingly interested in anti-aging products with a growing preference for products derived from natural substances and the desire to avoid pharmaceutical polypharmacy.
(3) The rapidly increasing cost of traditional pharmaceuticals many of which are not tied to exceptional clinical outcomes.
(4). Increasing knowledge (and prevalence) of ‘pre-clinical’ conditions such as prediabetes, pre-hypertension, metabolic syndrome and overweight syndrome for which pharmaceuticals are not indicated and/or ineffective and for which most consumers have a preference for food.
CAEH CEO John Boschert commented, "These new developments continue our aggressive movement into the nutraceutical marketplace and complement our pharmaceuticals pipeline in a way that provides for diverse product lines all based on our expertise in identifying and developing products based on natural compounds."
"The strategic alliance with Natac provides further confirmation that our dual-pathway commercialization plans and our unique market entry strategies are of interest to experts in the high-science pharmaceutical and over-the-counter consumer-oriented fields," he further stated.
Get your research started by going to CAEH's website at: http://www.calecopharmacorp.com/
No comments:
Post a Comment